<DOC>
	<DOC>NCT00100620</DOC>
	<brief_summary>The intake of high doses of corticosteroids is known to play an important role in the weakening of the bones and is thus an increasing fracture risk. Zoledronic acid (Aclasta) is a drug known for its protective effect in some bone diseases (tumors, paget). This study will test the safety and efficacy of zoledronic acid in the prevention and treatment of corticosteroid induced osteoporosis in male and female patients.</brief_summary>
	<brief_title>Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Long duration treatment with corticosteroids (started or ongoing) History of osteogenesis imperfecta, multiple myeloma or Paget's disease History of Hyperparathyroidism, hyperthyroidism History of Osteomalacia Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Corticosteroid induced osteoporosis</keyword>
	<keyword>prevention</keyword>
	<keyword>treatment</keyword>
	<keyword>zoledronic acid</keyword>
</DOC>